Completed NA INTERVENTIONAL 2-arm
NCT00549874
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
Sponsor: GlaxoSmithKline
Conditions
Type 2 Diabetes
Interventions
Glyburide Rosiglitazone
Updated 5 times since 2017 Last updated: Nov 8, 2007 Started: Feb 28, 2002 Completion: Nov 30, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on Type 2 Diabetes, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Feb 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- GlaxoSmithKline
- University of Michigan
Data source: University of Michigan
For direct contact, visit the study record on ClinicalTrials.gov .